Cervical Cancer News and Research RSS Feed - Cervical Cancer News and Research

Cancer is a disease in which cells in the body grow out of control. Cancer is always named for the part of the body where it starts, even if it spreads to other body parts later. When cancer starts in the cervix, it is called cervical cancer. The cervix is the lower, narrow end of the uterus. Also known as the womb, the uterus is where a baby grows when a woman is pregnant. The cervix connects the upper part of the uterus to the vagina (birth canal).

Cervical cancer is highly preventable in most Western countries because screening tests and a vaccine to prevent HPV infections are available. When cervical cancer is found early, it is highly treatable and associated with long survival and good quality of life.
BioLight receives CE Mark approval for CellDetect bladder cancer test

BioLight receives CE Mark approval for CellDetect bladder cancer test

BioLight Life Sciences Investments Ltd., a firm that invests in, manages and commercializes biomedical innovations in ophthalmology and cancer diagnostics, announced today that its CellDetect non-invasive test for detecting bladder cancer in urine has obtained CE Marking, enabling the product to be marketed and sold in Europe and other territories. [More]
Study suggests link between fatalistic beliefs and completion of HPV vaccine series among Appalachian women

Study suggests link between fatalistic beliefs and completion of HPV vaccine series among Appalachian women

Could a fatalistic attitude toward cervical cancer serve as a barrier to prevention of the disease? A recent study conducted by University of Kentucky researchers in the Rural Cancer Prevention Center suggests a link between fatalistic beliefs and completion of the human papillomavirus (HPV) vaccine series among a sample of young Appalachian Kentucky women. [More]
The Mary Kay Foundation awards $1.3 million grant to advance cancer research and discovery

The Mary Kay Foundation awards $1.3 million grant to advance cancer research and discovery

With more than 800,000 new cases of cancer among women in the United States expected this year, according to the American Cancer Society, almost everyone is touched by the disease. [More]
WHO prequalifies new male circumcision device to prevent HIV

WHO prequalifies new male circumcision device to prevent HIV

The ShangRing, a novel medical device for voluntary medical male circumcision, has received prequalification from the World Health Organization (WHO) for use. [More]
Rates of high-grade cervical lesions decrease in young U.S. women following availability of HPV vaccines

Rates of high-grade cervical lesions decrease in young U.S. women following availability of HPV vaccines

A new analysis indicates that rates of high-grade cervical lesions decreased in young U.S. women after vaccines were made available to protect against human papillomavirus (HPV), but the trend may be due in part to changes in cervical cancer screening recommendations. [More]
PD linked to increased cancer risk in Asian population

PD linked to increased cancer risk in Asian population

A Taiwanese population-based cohort study reports an increased risk of most cancers in patients with Parkinson’s disease, contrasting with findings in Western populations. [More]
Bivalent HPV vaccine efficacy may be independent of dose

Bivalent HPV vaccine efficacy may be independent of dose

Fewer than three doses of the bivalent human papillomavirus vaccine may be sufficient to offer adequate protection against cervical HPV-16 and -18 infection, research published in The Lancet Oncology indicates. [More]
Nanoplatform technology that detects early stages of cancer receives U.S. patent

Nanoplatform technology that detects early stages of cancer receives U.S. patent

A U.S. patent has been awarded to a Kansas State University technology that quickly detects the early stages of cancer before physical symptoms ever appear. [More]
CINtec PLUS Cytology test more effective than HC2 HPV test in identifying women with precancerous lesions

CINtec PLUS Cytology test more effective than HC2 HPV test in identifying women with precancerous lesions

Ventana Medical Systems, Inc., a member of the Roche Group, today announced the publication of further results from the Primary ASC-US LSIL Marker Study (PALMS) in this month's issue of Cancer Cytopathology. The PALMS study, which enrolled more than 27,000 women from five European countries, was designed to evaluate the diagnostic performance of the CINtec PLUS Cytology test in detecting pre-cancerous cervical disease compared to HPV testing and more traditional screening methods like Pap cytology. [More]
Genticel’s GTL001 phase 1 clinical study of HPV therapeutic vaccine granted FDA clearance

Genticel’s GTL001 phase 1 clinical study of HPV therapeutic vaccine granted FDA clearance

Genticel, a French biotechnology company and developer of innovative immunotherapies to prevent cancers caused by the human papillomavirus, today announces that the US Food and Drug Administration (FDA) has cleared Genticel’s Investigational New Drug application to conduct in the US a phase 1 clinical study of GTL001 in patients infected with HPV 16 and/or 18, the two HPV types responsible for 70% of cervical cancer cases. [More]
Keele University academic calls for urgent review of cervical screening programmes

Keele University academic calls for urgent review of cervical screening programmes

As Cervical Screening Awareness Week begins, a Keele University academic is calling for cervical screening programmes and perceptions of cervical cancer to be reviewed urgently, to encourage more older women to get regularly screened. [More]
Weill Cornell scientists reveal how XBP1 gene can trigger immune responses against ovarian tumors

Weill Cornell scientists reveal how XBP1 gene can trigger immune responses against ovarian tumors

Ovarian cancer shuts down immune system cells that would otherwise act as a first line of defense against the deadly tumor, Weill Cornell Medical College scientists report today. But a therapy that restores the cells' disease-fighting abilities could provide a powerful new strategy to attack the cancer, which kills more than 14,000 women each year. [More]
Nearly 15 million U.S. women have limited access to specialized gynecologic cancer care

Nearly 15 million U.S. women have limited access to specialized gynecologic cancer care

More than one-third of counties in the Unites States are located more than 50 miles from the nearest gynecologic oncologist, making access to specialty care for ovarian and other gynecologic cancers difficult for nearly 15 million women. While most of these "low access" counties are located in the Mountain-West and Midwest regions, the findings of a recent study from researchers at the Perelman School of Medicine at the University of Pennsylvania also reveal that 47 states have at least one county located more than 50 miles from the nearest gynecologic oncologist. [More]
New study shows that estrogen receptors vanish in cervical cancer tumors

New study shows that estrogen receptors vanish in cervical cancer tumors

Scientists have prior evidence that the hormone estrogen is a major driver in the growth of cervical cancer, but a new study examining genetic profiles of 128 clinical cases reached a surprising conclusion: Estrogen receptors all but vanish in cervical cancer tumors. [More]
Single dose of Cervarix vaccine effective in preventing HPV infections

Single dose of Cervarix vaccine effective in preventing HPV infections

A single dose of the human papillomavirus (HPV) vaccine Cervarix appears to be as effective in preventing certain HPV infections as three doses, the currently recommended course of vaccination. [More]
Cell fusion triggers multiple genetic changes that convert normal cells to cancer cells

Cell fusion triggers multiple genetic changes that convert normal cells to cancer cells

Although there is no one established universal cause of cancer, genetic changes are central to its development. The accumulation of spontaneous genetic changes, or mutations, that occur when cells divide can be hastened by exposure to carcinogens such as cigarette smoke (lung cancer) and infectious agents such as the papillomavirus (cervical cancer). [More]
Chronic exposure to bacteria may lead to development of Type 2 diabetes

Chronic exposure to bacteria may lead to development of Type 2 diabetes

Bacteria and viruses have an obvious role in causing infectious diseases, but microbes have also been identified as the surprising cause of other illnesses, including cervical cancer (Human papilloma virus) and stomach ulcers (H. pylori bacteria). [More]
Genticel announces positive results of new multivalent HPV therapeutic vaccine based on Vaxiclase platform

Genticel announces positive results of new multivalent HPV therapeutic vaccine based on Vaxiclase platform

Genticel, a French biotechnology company and developer of innovative immunotherapies to prevent cancers caused by the human papillomavirus (HPV), announces today positive preclinical in vivo proof of concept results of GTL002, its multivalent HPV therapeutic vaccine candidate based on the Company’s versatile Vaxiclase platform. [More]
FDA clears ADXS-HPV plus epacadostat IND for HPV-associated cervical cancer Phase 2 study

FDA clears ADXS-HPV plus epacadostat IND for HPV-associated cervical cancer Phase 2 study

Advaxis, Inc., a clinical-stage biotechnology company developing cancer immunotherapies, today announced the clearance of the Investigational New Drug application by the United States Food and Drug Administration to conduct a Phase 2 study of ADXS-HPV (ADXS11-001) alone or in combination with Incyte Corporation's investigational oral indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor, epacadostat (INCB24360), for the treatment of Stage I-IIIb human papillomavirus (HPV)-associated cervical cancer. [More]
Clinical utility of Caris Molecular Intelligence in five studies to be presented at ASCO 2015

Clinical utility of Caris Molecular Intelligence in five studies to be presented at ASCO 2015

Caris Life Sciences, a leading biotechnology company focused on fulfilling the promise of precision medicine, today announced the presentation of data from five studies that demonstrate the clinical utility of Caris Molecular Intelligence®, the company's panomic comprehensive tumor profiling service, in helping to identify targeted treatment options for patients with rare and/or aggressive tumors. [More]
Advertisement